Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00134979|
Recruitment Status : Completed
First Posted : August 25, 2005
Last Update Posted : October 25, 2011
This study is not being conducted in the United States.
This study is designed to provide efficacy and safety data for formoterol 10µg twice-a-day (b.i.d.) delivered by the Certihaler in patients with chronic obstructive pulmonary disease (COPD). This study is also designed to compare the efficacy and safety of therapy with formoterol (Certihaler)10µg b.i.d. added to tiotropium (HandiHaler) 18µg once daily (o.d.) compared with tiotropium (HandiHaler) 18µg o.d. monotherapy, and to compare the safety and efficacy of formoterol 10µg b.i.d. (Certihaler) with tiotropium 18µg o.d. (HandiHaler).
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Drug: Formoterol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||847 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||November 2005|
|Actual Study Completion Date :||November 2005|
- Forced Expiratory Volume in 1 second measured at 2 h post dosing following 24 weeks treatment
- Forced Expiratory Volume in 1 second measured pre-dose, 5 minutes, 2 h and 3 h post dose at day 1, week 12 and week 24
- Forced Vital Capacity measured pre-dose, 5 minutes, 2 h and 3 h post dose at day 1, week 12 and week 24
- St. George's Respiratory Questionnaire following 12 and 24 weeks of treatment.
- COPD "Bad Days" recorded throughout study
- COPD "Exacerbation days" recorded throughout study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134979
|Novartis Pharma AG, Switzerland|
|Study Chair:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|